START - Early Thrombocyte Administration to Patients With Ruptured Abdominal Aortic Aneurism

Thrombocyte Administration Versus no Thrombocytes to Patients With Ruptured Abdominal Aortic Aneurism Before Transport to Hospital With Vascular Surgical Department

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01291290

Acronym

rAAA

Enrollment

420

Registered

2011-02-08

Start date

2010-03-31

Completion date

2015-03-31

Last updated

2013-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ruptured Abdominal Aortic Aneurism

Keywords

rAAA, Platelets, TEG, Massive bleeding, Coagulopathy

Brief summary

The purpose of this study is to investigate the effect of platelet infusion prior to transfer to a vascular surgical department in patients with a ruptured abdominal aortic aneurism.

Interventions

PROCEDUREPlatelet

2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* diagnosed with rAAA either by clinical evaluation or CT or UL

Exclusion criteria

* formerly randomized in the study * aneurism not ruptured during operation

Design outcomes

Primary

Measure	Time frame	Description
Mortality	30 days	Mortality during the first 30days after randomization, and time to death during the 30 days.

Secondary

Measure	Time frame	Description
Acute myocardial infarction	30 days	Development of AMI during the first 30 days after randomization, and the time to development during the first 30 days.
Post operative kidney failure	30 days	The need for dialysis during the first 30 days, time to start of dialysis and length.
Post operative pulmonary insufficiency	30 days	Length of respirator treatment in the ICU during the first 30 days.
Length of stay in ICU	until discharged from ICU	Length of stay in ICU
Length of stay in hospital	until discharged from hospital	Until discharged from main surgical department or if transferred to local hospital, when the patient leave local hospital.

Countries

Denmark

Contacts

Primary ContactThomas Bech Jørgensen, MD

starttrial@gmail.com25620901

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026